New autoimmune diseases after cord blood transplantation: A retrospective study of EUROCORD and the autoimmune disease working party of the European group for blood and marrow transplantation

Thomas Daikeler, Myriam Labopin, Annalisa Ruggeri, Alessandro Crotta, Mario Abinun, Ayad Ahmed Hussein, Kristina Carlson, Jérôme Cornillon, Jose L. Diez-Martin, Virginie Gandemer, Maura Faraci, Caroline Lindemans, Anne O'Meara, Valerie Mialou, Marleen Renard, Petr Sedlacek, Anne Sirvent, Gérard Socié, Federica Sora, Stefania VarottoJaime Sanz, Jan Voswinkel, Ajay Vora, M. Akif Yesilipek, Andree Laure Herr, Eliane Gluckman, Dominique Farge, Vanderson Rocha

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

61 Citaten (Scopus)

Samenvatting

To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% ± 1% at 1 year and 6.6% ± 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P < .001). ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n = 9; autoimmune thrombocytopenia, n = 11; and immune neutropenia, n = 1) and other tissues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n = 1; membranous glomerulonephritis, n = 2; rheumatoid arthritis, n = 1; ulcerative colitis, n = 1; and systemic lupus erythematosus, n = 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs.

Originele taal-2Engels
Pagina's (van-tot)1059-1064
Aantal pagina's6
TijdschriftBlood
Volume121
Nummer van het tijdschrift6
DOI's
StatusGepubliceerd - 7 feb. 2013
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'New autoimmune diseases after cord blood transplantation: A retrospective study of EUROCORD and the autoimmune disease working party of the European group for blood and marrow transplantation'. Samen vormen ze een unieke vingerafdruk.

Citeer dit